PARIS, June 26, 2025--Orano Med, a pioneer in radioligand therapies in oncology, inaugurated the expansion of its R&D Center located in Plano, Texas (USA).

Orano Med, a subsidiary of the Orano Group and a pioneer in radioligand therapies in oncology, today inaugurated the expansion of its main Research and Development Center located in Plano, Texas ...

With an investment of over $5 million, Orano Med has expanded its R&D Center by approximately 11,000 ft². The expansion includes around 5,000 ft² of new laboratory space, enabling the advancement of a ...

Approximately 75,000 new residents are expected to move to Knox County by 2040. Who are they, and where are they coming from?

Molecular Partners AG and Orano Med have announced the development of MP0726, a Radio-DARPin candidate targeting mesothelin (MSLN) for ovarian cancer treatment, which shows promising tumor ...

Orano Med, a firm that combines biotechnologies and nuclear technology to develop targeted therapies against cancer, has ...

MP0726, a Radio-DARPin candidate targeting mesothelin (MSLN) and intended for the treatment of ovarian cancer, is nominated for development under strategic partnership with Orano MedPromising ...

MP0726 is being co-developed under Molecular Partners’ strategic partnership with Orano Med. “Our collaboration with Molecular Partners has been delivering substantial progress in a short time, ...

Molecular Partners and Orano Med are developing targeted alpha radio-therapeutics against up to ten targets, including the tumor-associated protein Delta-like ligand 3 (DLL3) and mesothelin (MSLN).